Last reviewed · How we verify
GU-01: Glycyrrhizin in Prostate Cancer: A Window-of-Opportunity Trial
This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer (PCa) who are candidates for surgery (radical prostatectomy)
Details
| Lead sponsor | University of Illinois at Chicago |
|---|---|
| Phase | Phase 2 |
| Status | RECRUITING |
| Enrolment | 60 |
| Start date | 2024-07-25 |
| Completion | 2027-03 |
Conditions
- Prostate Cancer
Interventions
- Observation
- Glycyrrhizin - 75 mg
- Glycyrrhizin - 150 mg
Primary outcomes
- To evaluate anti-tumor activity of GLY by assessing changes in prostate-specific antigen (PSA) after GLY treatment administration and prior to radical prostatectomy — 2 months
Changes in prostate specific antigen (PSA) in patients with prostate cancer will be assessed before and after administration of GLY
Countries
United States